Immunovant, Inc. Profile Avatar - Palmy Investing

Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
Government, Law & Regulation

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Immunovant, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
0.0 IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
YoY Trends
  • No trends presentable at the moment.

Spending By Type

Awards
Obligations
Contracts IDV Contracts Grants Loans Direct Other

Immunovant, Inc. can't present spending by time.

Contract Analysis

There are no contract award details available for Immunovant, Inc.

End of IMVT's Analysis
CIK: 1764013 CUSIP: 45258J102 ISIN: US45258J1025 LEI: - UEI: -
Secondary Listings
IMVT has no secondary listings inside our databases.